Affibody's Licensee Rallybio Announces Preliminary Phase 1 MAD Data for RLYB116 -December 20, 2023 at 09:33 am EST : vimarsana.com

Solna, Sweden, December 20, 2023. Affibody’s licensee Rallybio Corporation today announced preliminary Phase 1 multiple ascending dose data for RLYB116, an innovative, long-acting, low volume...

Related Keywords

Sweden , Solna , Stockholm , David Bejker , Rallybio Corporation , Patricia Industries , Nordic Press , Licensee Rallybio Announces Preliminary Phase , Results Demonstrated , Mean Reduction , Low Volume Weekly Subcutaneous , Differentiated Therapeutic , Generalized Myasthenia , Modular Finance , Markets ,